0
0.0
Jan 31, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
so let me just begin with novartis. as you can see, one of the biggest downmovers right at the bottom of the stoxx 600, more than 4.3%. we'll talk to sylvia about what's going on there. she spoke with the ceo a short while ago. compare that to know vnovo nordisk. growing by more than 26% this year. what's aiding them is their blockbuster obesity drugs, wegovy. the orders keep coming thick and fast. again, charlotte is going to be speaking to the ceo in a couple of minutes about how the outlook looks for novo nordisk in 2024. >>> in the retail sector, look at h&m. it's not a pretty day at all for the world's second largest retailer. you can see the stock is down more than 6.6% after a surprise change in the ceo and a weak festive period. it didn't match up to what they had priced in. the stock is down 7%. >>> and then finally in banking space, we've had a bunch of span is banks report the last couple of days. yesterday we had bbva come in with solid results and today up half a percent after a 28% jump. so many banks have
so let me just begin with novartis. as you can see, one of the biggest downmovers right at the bottom of the stoxx 600, more than 4.3%. we'll talk to sylvia about what's going on there. she spoke with the ceo a short while ago. compare that to know vnovo nordisk. growing by more than 26% this year. what's aiding them is their blockbuster obesity drugs, wegovy. the orders keep coming thick and fast. again, charlotte is going to be speaking to the ceo in a couple of minutes about how the outlook...
0
0.0
Jan 31, 2024
01/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
that is the top line coming through from novartis. net sales and core eps slightly below the estimate. we are also going to talk about what's been coming through from santander. earnings came through in 15 minutes ago. before we get them, we are going to be speaking to executives at of course novartis, the ceo at 7:30 u.k. time. so let's get to the santander members as well now. the red headline coming through, a big retail exposure. fourth quarter net income coming in as a beat for santander. 2.9 3 billion euros. versus the estimate of 2.5 6 billion. net interest income really important given the focus on the overall rate situation for the fourth quarter. net interest income above estimates as well as 11.1 billion. above the estimates of just shy of 11 billion euros. the red headline fourth quarter, it was a beat for that spanish lender. santander's chair will join our markets today program to discuss those earnings. stay, 7:40 london time. let's get you up-to-date on the markets. we look ahead to the federal reserve decision with a
that is the top line coming through from novartis. net sales and core eps slightly below the estimate. we are also going to talk about what's been coming through from santander. earnings came through in 15 minutes ago. before we get them, we are going to be speaking to executives at of course novartis, the ceo at 7:30 u.k. time. so let's get to the santander members as well now. the red headline coming through, a big retail exposure. fourth quarter net income coming in as a beat for santander....
0
0.0
Jan 9, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >> site toe kinetics, novartis. the ceo is here.k he doesn't have to talk about it. i'm not going to let him get away with that. obviously he just heard that. there is no preparation other than truth. david, you know you can't have a $9 billion company potential acquisition and not talk about it. that's not fair to the people who are buying it. >> that's true. in fact, the stock was down at this time yesterday in part because they presented as well, i believe, with jpmorgan. there was no mention made. and/or no announcement, because we came in yesterday perhaps expecting there would be a deal given previous reporting on such possibility. later in the day, as you referenced, the journal reported they were still very close to that deal with novartis. so we'll see. >> should i ask -- >> of course you should ask him. he's probably going to "no comment" you, unless there's a press release between now and then. you've got to ask him. >> i should accept no comment. i should say, sorry about the biggest story out there. if he gives you no c
. >> site toe kinetics, novartis. the ceo is here.k he doesn't have to talk about it. i'm not going to let him get away with that. obviously he just heard that. there is no preparation other than truth. david, you know you can't have a $9 billion company potential acquisition and not talk about it. that's not fair to the people who are buying it. >> that's true. in fact, the stock was down at this time yesterday in part because they presented as well, i believe, with jpmorgan. there...
0
0.0
Jan 9, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >>> novartis is closing in on the deal to buy cytokinetics for $10 billion.euters says the takeover deal could be announced as soon as this week. a small dip in the shares of novartis is down this morning. >>> and hays is missing the forecast for the year after the fees drop 10% at the start of the year. the recruitment firm saying it is too soon to say with the challenging conditions. hays is not in the ftse 100, it is in the ftse 250. that is dragging down the other recruiters. >>> in auto space, bmw reported 10.3% growth in the quarter selling 2.56 million units in 2023. it hit the target of 15% share of battery electric vehicles and says it does not see any need to cut prices in line with some rivals. still a dip in terms of the shares this morning down .40%. >>> elsewhere, volkswagen reported a 6.7% increase of sales in 2023 with sales of electric vehicles jumping over 21%. >>> we are waiting for trade from grifols after citi research accused it of manipulating the numbers and called it uninvestable. the spain stock investor is analyzing the report. we h
. >>> novartis is closing in on the deal to buy cytokinetics for $10 billion.euters says the takeover deal could be announced as soon as this week. a small dip in the shares of novartis is down this morning. >>> and hays is missing the forecast for the year after the fees drop 10% at the start of the year. the recruitment firm saying it is too soon to say with the challenging conditions. hays is not in the ftse 100, it is in the ftse 250. that is dragging down the other...
0
0.0
Jan 8, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
. >>> check out shares of novartis and cyto kinnetics as "the wall street journal" reports that novartis is nearing a deal to buy cytokinetics and no details yet on the potential price and cyt shares are popping 16% and super busy on this front lately. speaking of which, one of the biggest health care, vents of the year is taking place in california. j.p. morgan is coming under debate over the impact of those new weight loss drugs and they can lessen demand for hip and knee replacements going forward ahead for the medical device makers and share of medtronic is coming off a three-year string of declines. how is the company responding to all of these challenges? let's get out to cnbc's very own jim cramer. he's at the j.p. morgan healthcare company with medtronics ceo. jim, over to you. >> oh, thank you so much, kelly. he'll go right to the issue. there may not be nearly as much impact for diabetes and cardiovascular as people are thinking. >> right. first of all, thanks for having me, jim. it's great to be here. on the topic, first, these are important new drugs for patients and having a
. >>> check out shares of novartis and cyto kinnetics as "the wall street journal" reports that novartis is nearing a deal to buy cytokinetics and no details yet on the potential price and cyt shares are popping 16% and super busy on this front lately. speaking of which, one of the biggest health care, vents of the year is taking place in california. j.p. morgan is coming under debate over the impact of those new weight loss drugs and they can lessen demand for hip and knee...
0
0.0
Jan 9, 2024
01/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
novartis has reported to be close to acquiring a company and an important drug.ket value ofbillion couls soon as this week. a potential takeover as big pharma companies continue to step up bio text to improve drug pipelines and diversify their portfolios. we have identified 50 companies from finance to food that warrant a closer look in 2024. their analysis combining contrarian views and upcoming catalyst for change like new leadership, acquisitions and plans for new products and services. for more, i am joined by tim. there is a lot to digest here, i want to dive in impute talking about some of these -- dive in . this idea that it feels like there has been so much excitement and acceleration around ai, it feels like this will be the year of execution, would you agree? tim: i would totally. if you go back to i think it was mckinsey that came up with the idea of the hype cycle and quite often things get really crazy and then there is this void as things get implemented. you think about that with 3g, 4g, 5g, ar. ai had some big hype in 2023. we published a notable
novartis has reported to be close to acquiring a company and an important drug.ket value ofbillion couls soon as this week. a potential takeover as big pharma companies continue to step up bio text to improve drug pipelines and diversify their portfolios. we have identified 50 companies from finance to food that warrant a closer look in 2024. their analysis combining contrarian views and upcoming catalyst for change like new leadership, acquisitions and plans for new products and services. for...
0
0.0
Jan 9, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
the wall street journal is reporting that novartis is close to making a deal for cytokinetics.ne drug could estimate up to $3.6 billion of sales by 2032. this includes the deal for amblos. it is coinciding with the jpmorgan chase healthcare conference where jim cramer is there. one big player is obesity and weight loss. >> 4 billion people are likely to be obese by 2025. that is a massive market opportunity. most analysts peg the obesity market around $100 billion. there will be many opportunities for many players to be in the market. >> we have about a half dozen other projects, that we are generating data for. we think overnight time, there be a need of medicines to address the global obesity epidemic. >> our coverage of the jpmorgan chase covenference continues at 10:15 a.m. eastern with the ceo of eli lilly. >>> the big money movers and retailer popping ahead of the open. a bk ghafr iswereacrit teth. what is cirkul? cirkul is the fuel you need to take flight. cirkul is the energy that gets you to the next level. cirkul is what you hope for when life tosses lemons your way.
the wall street journal is reporting that novartis is close to making a deal for cytokinetics.ne drug could estimate up to $3.6 billion of sales by 2032. this includes the deal for amblos. it is coinciding with the jpmorgan chase healthcare conference where jim cramer is there. one big player is obesity and weight loss. >> 4 billion people are likely to be obese by 2025. that is a massive market opportunity. most analysts peg the obesity market around $100 billion. there will be many...
0
0.0
Jan 26, 2024
01/24
by
BLOOMBERG
tv
eye 0
favorite 0
quote 0
katie: eli lilly was late to the drug business behind novartis but the new shot is expected to be theselling drug of all time. >> when i look around i can't help but wonder is stkoepl ozempic right for me. it 2022 it started entering the consciousness. >> it is great for people boss parents cannot cook. >> the biggest corporate beneficiary of the pop larry is their company with $450 billion but a new contender entered the ring. eli lilly has a competing drug and looks to be more effective and keeper. it set off a horse race between these two to see who will take the biggest part of it enormous market. >> in 2019 they traded at comparable levels to the rest of the pharma industry. since june of 2021 when it was approved the stock evaluation have soared tracking with companies such as apple on how much they are likely to grow the next few years. the market was worth $2.5 billion in 2022. we might it could be in excess of $80 billion by 2030 because we have two competitors in the space and it will make the whole market bigger. katie: that was a look at eli lilly's foray into the business
katie: eli lilly was late to the drug business behind novartis but the new shot is expected to be theselling drug of all time. >> when i look around i can't help but wonder is stkoepl ozempic right for me. it 2022 it started entering the consciousness. >> it is great for people boss parents cannot cook. >> the biggest corporate beneficiary of the pop larry is their company with $450 billion but a new contender entered the ring. eli lilly has a competing drug and looks to be...
0
0.0
Jan 31, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
on the farming sector, novartis stock is down almost 4% after a fourth quarter stock miss. >>> san taners profits beat expectations. and novo nordisk up a little bit, up a tenth of a percent. it's europe's most valuable company, a new record-high for the stock after they see sales grow 26% this year. it's a mixed bag when it comes to earnings, but overall the sentiment is somewhat mixed. >> joumanna bercetche in our london newsroom. >>> it will be the first time boeing opens its books since the midair alaska airlines door plug blowout this month. joining me now with more is ken herbert, aerospace and equity research analyst at rbc. you have a price target of 285, stocks trading at 200. it's your least favorite, but you seem pretty optimistic. >> yes. we're still pretty optimistic in the long term. travel continues to hold up pretty well we think the cash outlook the company previously provided probably had a little bit of pressure. we do feel that $200 share of the set junk over the longer term remains favorable. although when we published on our preview, we said the outlook is certain
on the farming sector, novartis stock is down almost 4% after a fourth quarter stock miss. >>> san taners profits beat expectations. and novo nordisk up a little bit, up a tenth of a percent. it's europe's most valuable company, a new record-high for the stock after they see sales grow 26% this year. it's a mixed bag when it comes to earnings, but overall the sentiment is somewhat mixed. >> joumanna bercetche in our london newsroom. >>> it will be the first time boeing...
0
0.0
Jan 17, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
our sylvia spoke to novartis's ceo and what he expects for 2024. >> the biotech sector is really a 10h that in recent years you've seen cash come out from the companies as they burn through it as they continue to run through the program. now i think we're seeing an openness in biotech. and with companies like ours that have been streamlined down, we need to bring the next wash of innovations into the organization so i think there is a moment right now where you're going to see some pickup. we saw some pickup december was a pretty active time in the biotech sector, and i would expect that to continue over the course of the year. the one thing i would say has to be underpinned by strong science, of course, we only want to partner with companies with sound science and continue with the innovations they're working on. >> ester baiget joins us in studio lovely bright and green, bringing color you're almost over the line. you're still waiting for final approval from the e.c. are you going to get it to create this design >> it's a beautiful company. i wouldn't call it a mega giant, but, yes,
our sylvia spoke to novartis's ceo and what he expects for 2024. >> the biotech sector is really a 10h that in recent years you've seen cash come out from the companies as they burn through it as they continue to run through the program. now i think we're seeing an openness in biotech. and with companies like ours that have been streamlined down, we need to bring the next wash of innovations into the organization so i think there is a moment right now where you're going to see some...
0
0.0
Jan 8, 2024
01/24
by
CNBC
tv
eye 0
favorite 0
quote 0
journal reporting recently that novartis is planning a takeover of cytokinetic, switch has a promisingon. this flurry of deal making, not a coincidence. it comes amid the jpmorgan health care conference taking place in san francisco. the reportedly 8000 people attending this year's event is an annual occurrence or health care companies can talk up the recent deals and discuss future ones. the conference comes on the heels of an active december, where just three pharma giants, abbvie, bristol-myers squibb and astrazeneca scooped up nearly 30 billion dollars worth of drugmakers. the prospect of more deal making as well as those declining interest rates set the spider s&p biotech etf surging about 25%. since the start of december. lots of, high lots of excitement surrounding this space, scott. >> are we going to be talking, leslie, about other sectors that health care when it comes to a deal and a pick up? it's just the beginning, do you think? >> it's interesting. because one of the key drivers of mna is very health care specific, that a lot of these companies are facing patent cliffs. w
journal reporting recently that novartis is planning a takeover of cytokinetic, switch has a promisingon. this flurry of deal making, not a coincidence. it comes amid the jpmorgan health care conference taking place in san francisco. the reportedly 8000 people attending this year's event is an annual occurrence or health care companies can talk up the recent deals and discuss future ones. the conference comes on the heels of an active december, where just three pharma giants, abbvie,...